Ligand PharmaceuticalsLGND
ASignal's systematic analysis rates LGND as Bullish.
Reflects the latest available analysis · analyzed Sep 2, 2026
The case on LGND
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong revenue growth (33.7% YoY)
- Exceptional earnings growth (825% YoY)
- High gross margin (81.2%) indicating pricing power
- Positive free cash flow ($139.75M)
- Strong return on equity (21.96%)
- Current price near lower Bollinger Band, suggesting potential mean reversion
- MACD below signal line with negative histogram, indicating bearish momentum
- Price below SMA20 and SMA50, suggesting short-term downtrend
- High PEG ratio (1.53x) implies potential overvaluation relative to growth
- Elevated EV/EBITDA (40.91x) and P/E (29.70x) suggest rich valuation
- No Reddit mentions, indicating low retail investor interest or engagement
See the full verdict on LGND
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes LGND
Most investors never get a second opinion, let alone several. ASignal runs LGND past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.